Find cancer before it finds you
Find cancer before it finds you
Detect and eliminate
cancer at its start
Today, the cancer problem is a race against time. Cancer is diagnosed much too late. At least 40% of cancers are diagnosed at advanced or metastatic stage, when the available treatments are less effective. Patients suffer more greatly and are less likely to survive as a result of late diagnosis.
Early diagnosis has been demonstrated to be the most powerful strategy to defeat cancer. By enabling earlier and lighter treatments, early diagnosis avoids suffering, life-altering side effects, and cancer recurrence.
However, detecting cancer at an early stage is difficult since reliable, non-invasive screening tests are only available for a minority of cancers. Even if there were a test available for each type of cancer, regular screening for hundreds of possible cancers would be an arduous task for patients and result in exorbitant costs to the healthcare system.
Innovative test captures early cancer signals
The early diagnosis solution to the “cancer” problem lies in innovative “liquid biopsy” technology. In stark contrast to standard tissue biopsies, these non-invasive tests use bodily fluids to look for signs that cancer is developing in the body. Through a simple blood draw, it is possible to capture the first and faintest signals shed by cancer developing in any part of the body. This strategy requires the most advanced and innovative bio-molecular techniques, which are at the core of Rarecells development work.
Rarecells has been working for more than 10 years in the field of blood analysis targeting early cancer detection. We have developed a unique CE-IVD certified technology (ISET®) to discover very early signals of cancer in blood. The ISET® technology enables Rarecells to leverage detection of those early signals into life-saving cancer tests. Rarecells is also partnering with diagnostic and pharma companies to bring its innovative tests to patients.
Our passion
for transforming cancer care
Rarecells has a talented and dedicated team who is developing highly sensitive cancer tests that identify and analyze cancer cells. The idea that we can transform cancer care through early detection drives us every day.
Rarecells’ original research was conducted in France. The company is now established in the United States, with clinical collaborations with leading universities and research centers.
Working with researchers to revolutionize cancer care
Across the globe, researchers are doing amazing work to better understand how to defeat cancer. They universally agree on what is now demonstrated by facts: earlier cancer detection is the safest and most effective strategy to eliminate cancer and save lives.
At Rarecells, we are physicians and scientists using clinical experience and scientific first-in-class innovation to develop life-saving tests and bring them to patients. By leveraging state-of-the-art methods in DNA sequencing and circulating tumor cells detection, all powered by artificial intelligence, we have proven that cancer can be found at very early stages and definitively eliminated.
With more than 125 independent publications, Rarecells’ ISET® technology is a unique, reliable and scientifically proven technology in the field of liquid biopsy, with demonstrated efficacy for all types of cancer.